

Ausgabe: face 3/2016
Thema: Acne inversa - Versorgung in der Praxis
Autor: Dr. med. Uwe Schwichtenberg

Literatur

1. Kurzen H. et al. What causes hidradenitis suppurativa? 17:455-72. Exp Dermatol 2008.
2. Revuz, J. E. et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J. Am. Acad. Dermatol. 59, 596–601 (2008).
3. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):191-4.
4. von der Werth, J. & Williams, H. The natural history of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 14, 389–392 (2000).
5. Cosmatos, I., Matcho, A., Weinstein, R., Montgomery, M. O. & Stang, P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J. Am. Acad. Dermatol. 68, 412–419 (2013).
6. Zouboulis CC et al. S1 - Leitlinie zur Therapie der Hidradenitis suppurativa / Acne inversa. Gültig bis: 31.12.2017. Zuletzt aufgerufen am 11.05.2016.
7. Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90:216-221.
8. Wolkenstein, P., Loundou, A., Barrau, K., Auquier, P. & Revuz, J. Quality of life impairment in hidradenitis suppurativa: A study of 61 cases. J. Am. Acad. Dermatol. 56, 621–623 (2007).
9. Mayo Health Clinic. Hidradenitis Suppurativa. Available at: <http://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/basics/definition/con-20027334>. Zuletzt aufgerufen am 04.05.2016.
10. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta dermato-venereologica 2011;91(3):328-332.
11. Shavit E, Dreier J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. JEADV.2014:1-5.
12. Rosner, I. A., Burg, C. G., Wisniewski, J. J., Schacter, B. Z. & Richter, D. E. The clinical spectrum of the arthropathy associated with hidradenitis suppurativa and acne conglobata. J. Rheumatol. 20, 684–687 (1993).
13. Church, J. M., Fazio, V. W., Lavery, I. C., Oakley, J. R. & Milsom, J. W. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int. J. Colorectal Dis. 8, 117–119 (1993).

14. Goischke, H. K. & Ochsendorf, F. R. [Acne inversa in Crohn's disease]. *Z. Für Gastroenterol.* 39, 965–969 (2001).
15. Bettoli, V. et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. *Br. J. Dermatol.* 174, 195–197 (2016).
16. Fimmel, S. & Zouboulis, C. C. Comorbidities of hidradenitis suppurativa (acne inversa). *Dermatoendocrinol.* 2, 9–16 (2010).
17. Jansen T, Altmeyer P, Plewig G. Acne inversa (alias hidradenitis suppurativa). *J Eur Acad Dermatol Venereol* 15: 532-40, 2001.
18. Sellheyer K, Krahl D. What causes acne inversa (or hidradenitis suppurativa)? - the debate continues. *J Cutan Pathol* 35:701-3, 2008.
19. Jemec GB. The symphology of hidradenitis suppurativa in women. *Br J Dermatol* 119:345-50, 1988.
20. Alikhan A, Lynch PJ, Eisen D. Hidradenitis suppurativa: A comprehensive review. *J Am Acad Dermatol* 60: 539-61, 2009.
21. Mortimer PS et al. Mediation of hidradenitis suppurative by androgens. *Br Med J (Clin Res Ed)*. 1986 Jan 25; 292(6515): 245–248.
22. Sartorius, K., Emtestam, L., Jemec, G. B. E. & Lapins, J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. *Br. J. Dermatol.* 161, 831–839 (2009).
23. Mühlstädt M, Bechara FG, Kunte C. Acne inversa (Hidradenitis suppurativa): Erkennen – Verstehen – Therapieren. *Der Hautarzt* 2013; 64:55–62.
24. Danby FW and Margesson LJ. Hidradenitis suppurativa. *Dermatol Clin.* 2010 Oct;28(4):779-93.
25. Danforth's obstetrics and gynecology. (Lippincott Williams & Wilkins, 2008).
26. U.S. National Library of Medicine. <https://ghr.nlm.nih.gov/condition/hidradenitis-suppurativa>.
27. Edwards, L., Lynch, P. J. & Neill, S. M. Genital dermatology atlas. (Lippincott Williams & Wilkins, 2011).
28. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: *Dermatologic Surgery. Principles and Practice* (Roenigk RK, Roenigk HH Jr, eds) 2nd edn. New York, 1996:623-45.
29. A novel hidradenitis suppurativa efficacy variable, HiSCR (hidradenitis suppurativa clinical response), is responsive to change with adalimumab therapy: Results of a phase II study. *J. Am. Acad. Dermatol.* 68, AB40 (2013).

30. HUMIRA®-Fachinformation, Stand April 2016.

31. Safety and Efficacy of Adalimumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Results from First 12 Weeks of PIONEER I, a Phase 3, Randomized, Placebo-Controlled Trial. Abstract #210 44th Annual Meeting of the European Society for Dermatological Research (ESDR), Copenhagen, Denmark 2014.

32. Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a phase 3, randomized, placebo-controlled trial. *J. Am. Acad. Dermatol.* 72, AB45 (2015).